Biovotion’s Everion™ used as central data pillar in Mundipharma's painfocus™ Digital Platform to Revolutionise Pain Management via AI
SINGAPORE, Aug. 6, 2018 /Mundipharma -- Mundipharma has announced the development of painfocus™, a revolutionary new end-to-end pain management solution that significantly increases the objectivity of pain measurement, something that has been historically difficult. This has the potential to completely transform how caregivers and doctors manage their patients' pain.
The painfocus™ platform combines Biovotion’s Everion® as standard data input with Biofourmis’ AI-empowered health analytics platform, Biovitals™, which uses advanced machine learning, combining multiple physiology biomarkers to calculate the presence and severity of pain.
"Pain affects up to 1.9 Billion people globally, with massive associated healthcare costs," says Mundipharma CEO, Raman Singh. "Currently there's significant room for improvement in how pain is evaluated, and we're working to address this through the innovative use of machine learning."
"The ability to objectively assign a value to pain has the potential to transform how clinicians assess and manage their patients, resulting in a more optimal care pathway," he added.To be able to measure pain has always been a challenge in the medical field. Many tests are too one-dimensional and only measure pain at one point of time, mostly determined by the physician. Using painfocus™ to continuously measure pain in an ambulatory setting will revolutionize how clinicians treat and manage their patients."
This is just one example of the impact Everion has on digitally transforming health and healthcare. Wherever high user adoption allowing also long term use, accuracy and reliability is needed, Everion becomes the device of choice providing 22 parameters and features continuously and in medical grade quality. Our medical IoT solution with the Everion wearable at its core has significant potential to positively impact in scientific discovery, to drive the value proposition of digital health per se & to permit numerous commercial applications. The common denominator is a shared vision to better understand the entire illness-wellness spectrum & particularly the dynamics of health deterioration.